Figure 1C illustrates this process (Komersová et al., 2005; Aroniadou-Anderjaska et al., 2023). Inhibiting AChE can maintain elevated levels of ACh by obstructing its degradation. Several compounds have demonstrated the ability to elevate ACh levels through AChE inhibition (Carotenuto et al., 2022; Akhoon et al., 2020; Marucci et al., 2021), indicating a potential avenue for enhancing Alzheimer’s disease treatment. However, these compounds often cause side effects (Akhoon et al., 2020). This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.